Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
SSE:600332
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
24.59
33.06
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
Accrued Liabilities
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
SSE:600332
|
Accrued Liabilities
¥2.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
19%
|
CAGR 10-Years
21%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Accrued Liabilities
¥2B
|
CAGR 3-Years
2%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Accrued Liabilities
¥620.1m
|
CAGR 3-Years
8%
|
CAGR 5-Years
39%
|
CAGR 10-Years
35%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Accrued Liabilities
¥128.5m
|
CAGR 3-Years
456%
|
CAGR 5-Years
130%
|
CAGR 10-Years
63%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Accrued Liabilities
¥1.5B
|
CAGR 3-Years
48%
|
CAGR 5-Years
46%
|
CAGR 10-Years
59%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Accrued Liabilities
¥146m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
Glance View
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd, a leading player in China's pharmaceutical industry, stands out for its robust portfolio of products and a commitment to innovation. Founded in 1997 and headquartered in the bustling city of Guangzhou, the company has carved out a significant market presence through its diverse offerings, which include traditional Chinese medicines, chemical pharmaceuticals, and healthcare products. With a strong focus on research and development, Baiyunshan invests heavily in modernizing its production processes and expanding its product lineup, positioning itself well to capitalize on the growing demand for healthcare solutions in China and beyond. Its strategic partnerships and distribution capabilities further enhance its competitive edge, making it not just a manufacturer, but a trusted provider within the healthcare ecosystem. Investors looking at Guangzhou Baiyunshan should note the company’s impressive financial trajectory, characterized by consistent revenue growth and healthy profit margins. The pharmaceutical sector in China is poised for expansion due to an aging population and increasing health awareness, factors that bode well for Baiyunshan's future. The firm’s proactive approach to regulatory compliance and quality assurance has earned it a solid reputation with both consumers and industry stakeholders. As the company continues to enhance its research capabilities and expand its market reach, it represents a compelling opportunity for investors seeking exposure to the burgeoning Chinese pharmaceutical market. With a seasoned management team at the helm and a clear growth strategy, Guangzhou Baiyunshan is not just navigating the complexities of the pharmaceutical landscape; it is poised to thrive within it.
See Also
What is Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd's Accrued Liabilities?
Accrued Liabilities
2.1B
CNY
Based on the financial report for Jun 30, 2024, Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd's Accrued Liabilities amounts to 2.1B CNY.
What is Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 10Y
21%
Over the last year, the Accrued Liabilities growth was -12%. The average annual Accrued Liabilities growth rates for Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd have been 3% over the past three years , 19% over the past five years , and 21% over the past ten years .
You don't have any saved screeners yet
